Sanofi and the Brand Institute have raised the bar in drug naming with the audacious use of not one, not two, but three of the same letter in a row for its new hemophilia treatment. That drug is ...
Partners Sanofi SA and Swedish Orphan Biovitrum AB (Sobi) said regulatory submissions are expected this year for once-weekly factor VIII therapy efanesoctocog alfa in hemophilia A following top-line ...
June 8 (Reuters) - The U.S. Food and Drug Administration has approved Pfizer's drug to prevent or reduce the frequency of ...
Pfizer PFE announced that the FDA has approved its anti-TFPI inhibitor Hympavzi (marstacimab) for the treatment of two ...
Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. Treatment focuses on managing bleeding episode symptoms with clotting factor replacement therapy, ...
Hemophilia A, also known as classic hemophilia or factor VIII deficiency, is a bleeding disorder. It occurs when certain proteins are missing in the blood, causing people to bleed and bruise easily.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results